Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has had its abstract for PTX-100 published on the American Society of Hematology (ASH) website ahead of the company’s presentation at the ASH conference.
Prescient CEO and managing director Steven Yatomi-Clarke said: “Prescient is very pleased to have this study accepted for presentation at the prestigious ASH conference, the most attended conference on hematologic diseases in the world, attended by international pharmaceutical and biotech companies and leading oncologists."
Abstract published
The abstract for the ASH offers interim findings from the Phase 1b clinical study assessing PTX-100's efficacy in patients with relapsed and refractory T-cell lymphoma (TCL).
The data cut-off for inclusion in this abstract was July 10, but the trial is still live, with patients still involved.
This abstract reveals that, as of the cut-off date, 14 TCL patients had received treatment, with 10 patients undergoing response assessments after four therapy cycles, resulting in an overall response rate of 40%.
Two CTCL patients (20%) experienced durable stable disease for more than six months, contributing to a 60% disease control rate.
The median progression-free survival (PFS) for all TCL patients was 5.3 months, while CTCL patients achieved 13.6 months, and PTCL patients reached 2.5 months.
Given the limited number of patients involved, the abstract adheres to reporting requirements by measuring median PFS.
Participation in conference
The publication of the abstract online precedes a scheduled presentation on Saturday, December 9 (US time) at the ASH conference. The full abstract is available for viewing online here.
Prescient will release the full results of the PTX-100 Phase 1b trial, including updated and additional data, on the next business day following the ASH presentation, which falls on December 11.
“The Phase 1b data continues to be very promising in this difficult-to-treat patient population. With the study ongoing, we look forward to presenting updated Phase 1b results in December, as previously advised,” Yatomi-Clarke said.